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The effects of enalapril, an angiotensin converting enzyme (ACE) inhibitor, and losartan, an angiotensin II receptor type I antagonist, were
investigated on alterations in myofibrillar ATPase activity as well as myosin heavy chain (MHC) content and gene expression in failing hearts
following myocardial infarction (MI). Three weeks after ligation of the left coronary artery, rats were treated with or without enalapril (10 mg/
kg/day), and/or losartan (20 mg/kg/day) for 5 weeks. The infarcted animals exhibited an increase in left ventricle (LV) end diastolic pressure
and depressed rates of LV pressure development as well as pressure decay. LV myofibrillar Ca2 +-stimulated ATPase activity was decreased in
the infarcted hearts compared with controls, MHC a-isoform content was significantly decreased whereas that of MHC h-isoform was
markedly increased. The level of MHC a-isoform mRNAwas decreased whereas that of MHC h-isoform was increased in the viable infarcted
LV. Treatment of animal with enalapril, losartan, or combination of enalapril and losartan partially prevented the MI induced changes in LV
function, myofibrillar Ca2 +-stimulated ATPase activity, MHC protein expression and MHC gene expression. The results suggest that the
beneficial effects of the renin–angiotensin system blockade in heart failure are associated with partial prevention of myofibrillar remodeling.
D 2004 Elsevier B.V. All rights reserved.Keywords: Myosin heavy chain isoform; Myocardial infarction; Congestive heart failure; Myofibrillar ATPase; Cardiac gene expression; Angiotensin
converting enzyme inhibitor; Angiotensin II receptor antagonist
2 +1. Introduction
The ability of the cardiac muscle to generate contractile
force is primarily dependent upon myofibrillar Ca2 +-stimu-
lated ATPase activity [1]. Furthermore, it is known that the
myofibrillar ATPase activity is determined by different
amounts of myosin heavy chain (MHC) isozymes, namely
a-MHC and h-MHC in the myocardium [2,3]. A shift in the
composition of myosin isozymes with respect to a-MHC and
h-MHC contents has been shown to depress myosin ATPase
as well as myofibrillar Ca2 +-stimulated ATPase activities
and contractile function in different models of cardiac
hypertrophy and heart failure [3–8]. Recently, we have
observed that a significant shift from a-MHC to h-MHC
was associated with depressed myosin ATPase and myofi-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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due to myocardial infarction (MI) in rats [9]. However, the
mechanisms of such a change in the molecular composition
of myofibrils (myofibrillar remodeling) in congestive heart
failure (CHF) due to MI are not understood. Since the renin–
angiotensin system (RAS) is activated in CHF and its
blockade has been shown to prevent cardiac remodeling
(changes in cardiomyocyte size and shape) and improve
heart function in CHF due to MI in humans [10,11] and
animal models [9,12–15], it is likely that myofibrillar
remodeling in the failing heart is prevented by the blockade
of RAS. This view is based on our observation that treatment
of infarcted rats with imidapril, an angiotensin converting
enzyme (ACE) inhibitor, was found to attenuate depressions
in left ventricular (LV) function and myofibrillar Ca2 +-
stimulated ATPase activity as well as the changes in MHC
protein and gene expression [9]. No information is available
at present whether the effect of imidapril on myofibrillar
remodeling in the failing heart is simulated by other ACE
inhibitors or angiotensin II receptor antagonists.
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losartan, an angiotensin II receptor (AT1R) antagonist,
have been reported to produce beneficial actions on
cardiac remodeling and heart failure [15–17], the effects
of enalapril and losartan on changes in myofibrillar Ca2 +-
stimulated ATPase and MHC isoforms in CHF remain to
be examined. Thus, the present study was undertaken to
investigate if improvement of cardiac function is associat-
ed with prevention of changes in myosin isozymes and
gene expression for a-MHC and h-MHC, as well as
myofibrillar Ca2 +-stimulated ATPase activities in the fail-
ing heart upon treatment with enalapril or losartan. In
order to test if the effects of enalapril and losartan are
additive, infarcted animals were treated with a combination
of both drugs.2. Materials and methods
2.1. Experimental model
MI was induced in male Sprague–Dawley rats (175–
200 g) by occlusion of the left coronary artery as described
earlier [18–20]. Briefly, the heart in anesthetized animals
was exposed through left thoracotomy and the left coronary
artery was ligated at about 2 mm from origin of the aorta.
The heart was repositioned in the chest and the incision
was closed with a purse string suture. Sham-operated rats
were treated in the same way except that the artery was not
ligated. Mortality of experimental rats was approximately
35% within 48 h. Electrocardiography was performed
before and after open-chest to test the success of operation,
and also performed at 3 weeks following MI. All experi-
mental protocols were approved by the Animal Care
Committee of the University of Manitoba following guide-
lines established by the Canadian Institutes of Health
Research.
2.2. Treatment with enalapril and/or losartan
All animals received standard care, kept at 12-h day/
night cycle, fed regular rat chow and were provided water
ad libitum. The experimental animals were randomly di-
vided into five groups in this project: sham-operated
(Sham), infarcted (MI), enalapril treated infarcted (ENP),
losartan treated infarcted (LOS), and combined enalapril
and losartan treated infarcted (COM). Three weeks after the
operation, enalapril (10 mg/kg/day) and/or losartan (20 mg/
kg/day), or tap water was given orally via a gastric tube to
sham and infarcted groups for 5 weeks. The selection of the
doses for these drugs was based on our previous study
showing the beneficial effects of these agents on the
sarcoplasmic reticulum protein and gene expression in this
experimental model [15]. Enalapril and losartan were
supplied by Merck Research Laboratories (Rahway, NJ,
USA).2.3. Hemodynamic studies
At 8 weeks post-surgery, the animals were anesthetized
with an intraperitoneal injection of a mixture of ketamine
(60 mg/kg) and xylazine (10 mg/kg) and the right carotid
artery was exposed. A cannula with a microtip pressure
transducer (model SPR-249, Millar Instruments, Houston,
TX, USA) was introduced through proximal arteriotomy
[18,19]. The readings of pressures in aorta and LV were
taken from a computer program (AcqKnowledge for Win-
dows 3.0, Harvard Apparatus, Montreal, Canada). After the
hemodynamic measurement of LV end-diastolic pressure
(LVEDP), rate of pressure development ( + dP/dt), and rate
of pressure decay ( dP/dt) in the anesthetized animals, the
hearts were quickly removed, the LV (including septum)
and the scar tissue were dissected, weighed, frozen in liquid
nitrogen and stored at  70 jC. The lung wet/dry wt ratio,
an index of pulmonary congestion, as well as the heart wt/
body wt ratio, an index of cardiac hypertrophy, were
measured in these animals.
Since scar wt/total LV wt (including septum and in-
farcted tissue) ratio was found to exhibit a linear relation-
ship with infarct size (as measured morphometrically)
[9,15], the scar wt was used as a marker to determine
the extent of scar size. It should be pointed out that about
10% of untreated and treated animals showed small infarct
(scar wt/total LV ratio < 15% corresponding to scar size
< 30% of the free LV wall). Thus, the hemodynamic
data from the animals showing small infarct were not
included and the cardiac tissue from these animals was
discarded.
2.4. Myofibrillar Mg2+-stimulated ATPase and Ca2+-
stimulated ATPase activities
Myofibrils were isolated according to the procedure
employed earlier [9,21] and suspended in a final solution
containing 100 mM KCl, 20 mM Tris–HCl (pH 7.0). Mg2 +-
stimulated ATPase activity was determined at 30 jC in a
medium containing 20 mM imidazole (pH 7.0), 2 mM
MgCl2, 2 mM Na2ATP, 10 mM NaN3, 1.6 mM ethyl-
eneglucolbis (h-aminoethylether) N,N,NV,NV-tetraacetic ac-
id (EGTA) and 50 mM KCl. Total ATPase activity was
determined in the same medium except that EGTA was
replaced by 1 AM of free of Ca2 +. All reactions were
terminated after 5 min by the addition of 1 ml of 12%
trichloroacetic acid and the samples were centrifuged;
phosphate in the protein-free supernatant was determined
[22]. Ca2 +-stimulated ATPase activity was taken as the
difference between values obtained for total and Mg2 +-
stimulated ATPase activities.
2.5. Relative protein quantification of cardiac myosin
Relative protein contents of cardiac MHC and myosin
light chain (MLC) were determined by Western blot [9].
sica Acta 1690 (2004) 177–184
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enizer with Kinematica 87/Polytron PTA 7K1 for 4–6 s in
homogenizing buffer (100 Al buffer per 2 mg of muscle),
containing 60 mM KCl, 1 mM cysteine, 20 mM imidazole
(pH 6.9), 1 mM MgCl2, 1 mM oubain, 10 mM NaN3,
1 mM CaCl2, 0.01% leupeptin, 250 M phenylmethyl-
sulfonylfluoride and 1 mM dithiothreitol (DTT). The con-
centration of protein in the homogenate was adjusted to
1 mg/ml with the homogenizing buffer. The sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) loading buffer [0.25 M Tris–HCl (pH 6.8), 8% (w/
v) sodium dodecyl sulfate, 45% glycerol, 20% h-mercap-
toethanol, and 0.006% bromophenol blue] was added into
the homogenate buffer (1:3) [23]. The samples were boiled
for 5 min at 95 jC. The proteins in homogenate separated
by SDS-PAGE were electroblotted to Immobilon-P transfer
membrane (Millipore Company, Bellerica, MA, USA) in a
transfer buffer [25 mM Tris–HCl, 120 mM glycine and
20% methanol (v/v)]. The transferred membranes were
shaken for 2 h in blocking buffer, which contained TBS
(10 mM Tris–HCl, 150 mM NaCl) solution and 5% fat-
free powdered milk, then incubated for 1 or 2 h at room
temperature with monoclonal anti-MHC antibody, anti-
MLC mouse IgG antibody, or anti-TnI antibody (1:1000,
Sigma Immuno Chemicals, St. Louis, MO, USA). The
transferred membranes were subsequently incubated with
biotinylated anti-mouse IgG (1:1000, Amersham Bioscien-
ces, Baie d’Urfe, Canada) and then strepdavidin conjugated
horseradish peroxidase (1:5000, Amersham). The blots
were rinsed in the TBS-T (10 mM Tris–HCl, 150 mM
NaCl and 0.2% Tween-20) solution several times. For
chemilumnescent detection, the membrane sheets were
developed on Hyperfilm-ECL (Amersham) to visualize
proteins. The relative protein content was determined by a
GS-670 Imaging Densitometer (Bio-Rad Company, Hercu-
les, CA, USA) with the Image Analysis Software Version
1.0.
2.6. Analysis of cardiac MHC isoforms
Cardiac MHC isoforms were determined under denatur-
ing conditions. The a-MHC and h-MHC isoforms in theTable 1
General characteristics of myocardial infarcted rats with or without enalapril, and/o
Sham MI
Body weight (g) 505F 11 503F 13
Heart weight (mg) 1210F 90 1610F 110*
Scar wt (mg) ND 230F 15
Heart wt/BW (mg/g) 2.40F 0.12 3.20F 0.25*
Lung wet/dry wt 4.35F 0.1 5.51F 0.33*
Liver wet/dry wt 3.16F 0.3 3.26F 0.22
Values are meanF S.E. of seven animals in each group. ENP: myocardial infarcted
myocardial infarcted; COM: myocardial infarcted treated with both enalapril and
*P< 0.05 compared with Sham group.
# P< 0.05 compared with MI group.SDS-PAGE samples were separated by 4% SDS-PAGE as
described [5,9,24]. Electrophoresis was carried out at a
constant 220 V for 3–3.5 h with cooling between 13 and
17 jC and continuous stirring of bottom tank buffer. The
gels were stained with Coomassie brilliant blue R250 and
destained with 7% acetic acid by diffusion. Relative
amounts of isoforms were estimated by Imaging Densitom-
eter (GS-670, Bio-Rad).
2.7. RNA isolation and Northern blot analysis
Total myocardial RNA preparation was extracted from
the viable LV of sham, MI, ENP, LOS, COM rats by the
acid guanidinium thiocyanate–phenol–chloroform method
(TRIzol reagent, GIBCO-BRL Life Technologies, Paisley,
UK) according to the manufacturer’s instructions. The
RNA concentration was calculated from the absorbance at
260 and 280 nm. Steady-state levels of a-MHC and h-
MHC mRNA were determined by Northern hybridization
analysis [9]. After transferring, covalently cross-linked to
the matrix using UV radiation (UV Stratalinker 2400,
Stratagene, Cedar Creek, TX, USA), each membrane was
hybridized with 32P-labeled cDNA probes at 42 jC. Car-
diac a-MHC, h-MHC, MLC, and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) cDNA probes (American
Type Culture Collection) were labelled by random primer
DNA labelling system using Klenow fragment. Filters were
exposed to X-ray film (Kodak X-OMAT) at  80 jC with
intensifying screens. Results of autoradiographs from
Northern blot analysis were quantified by densitometry
(Bio-Rad imaging densitometer GS 670). The signal of
a-MHC, h-MHC and MLC mRNA was normalized to that
of GAPDH mRNA to account for differences in loading
and/or transfer.
2.8. Data analysis
Data are expressed as meanF S.E.. The differences
among various groups were evaluated statistically by
one-way ANOVA followed by the Newman–Keuls test.
A P value < 0.05 was taken to represent a significant
difference.r losartan treatment for 5 weeks starting at 3 weeks after coronary occlusion
ENP LOS COM
499F 19 505F 22 500F 23
1421F 68# 1387F 28# 1341F 27#
231F18 228F 11 229F 16
2.85F 0.22# 2.74F 0.13# 2.68F 0.20#
4.85F 0.18# 4.90F 0.30# 4.95F 0.31#
3.21F 0.16 3.19F 0.20 3.34F 0.16
treated with enalapril; LOS: myocardial infarcted treated with losartan; MI:
losartan; ND: not detected.
Fig. 1. Myofibrillar Mg2 +- and Ca2 +-stimulated ATPase activities of the left
ventricles from sham, infarcted (MI), enalapril-treated infarcted (ENP),
losartan-treated infarcted (LOS), and combined enalapril and losartan-
treated infarcted (COM) rats. ENP and/or LOS were given orally for 5
weeks starting at 3 weeks after inducing MI. Values are meansF S.E. of
seven animals for each group. *P< 0.05 vs. Sham; #P< 0.05 vs. MI.
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3.1. General characteristics and hemodynamic changes
Occlusion of the left coronary artery resulted in scar
formation in the LV, while the remaining cardiac muscle in
the 8-week infarcted animals underwent hypertrophy as
indicated by increased ventricular wt compared to the
sham control value (Table 1). A significant increase in
wet wt/dry wt ratio of the lungs indicated the presence of
pulmonary congestion in MI rats. The liver wet wt/dry wt
ratio was not altered. The depression in contractile function
in the 8-week untreated MI group was evident from an
increase in LVEDP and a decrease in both + dP/dt and
 dP/dt (Table 2). Changes in these parameters for general
characteristics and hemodynamics were partially (signifi-
cantly but not completely) prevented by treatment with
enalapril, losartan or combination of enalapril and losartan.
Furthermore, MAP in the untreated and treated groups was
not different from that in the sham control animals (Table
2). The alterations in treated and untreated MI groups
observed in this study are similar to those reported earlier
[9,13,15]. It was interesting that the combination therapy
did not produce additive effects as these values were not
different from those obtained by treatments with either
enalapril or losartan alone (Tables 1 and 2). The scar wt in
the untreated MI group was not different from the treated
groups.
3.2. Myofibrillar ATPase activities
Myofibrils isolated from the viable LV of infarcted
hearts exhibited a lower (7.1F 0.4 Amol Pi/mg/h) Ca2 +-
stimulated ATPase activity (P < 0.05) compared with sham-
operated rats (10.8F 0.4 Amol Pi/mg/h). Blockade of RAS
with enalapril and/or losartan partially normalized
( P < 0.05) the activity (8.3F 0.65, 7.9F 0.52, and
8.4F 0.58 Amol Pi/mg/h) in ENP, LOS and COM groups,
respectively (Fig. 1). The values for Ca2 +-stimulated
ATPase activity in COM group were not different from
that in ENP or LOS groups. Furthermore, no alterations ofTable 2
Hemodynamic parameters in myocardial infarcted rats with or without enalapril
occlusion
Sham MI
Heart rate (bpm) 265F 9 270F 13
LVSP (mm Hg) 122F 6.5 118F 4.6
LVEDP (mm Hg) 4.2F 0.3 18.9F 4.6*
+ dP/dt (mm Hg/s) 11,228F 850 8409F 687*
 dP/dt (mm Hg/s) 12,518F 1050 8524F 950*
MAP (mm Hg) 102F 9 100F 10
Values are meanF S.E. of seven animals in each group. ENP: myocardial infarc
COM: myocardial infarcted treated with both enalapril and losartan; LVEDP: left
MAP: mean arterial pressure; MI: myocardial infarcted.
*P< 0.05 compared with Sham group.
# P< 0.05 compared with MI group.myofibrillar Mg2 +-stimulated ATPase activity were found
among different groups (Fig. 1).
3.3. Protein content of MHC isoforms
The relative protein content of MHC was determined
from immunoblots using a monoclonal anti-MHC (a mix-
ture of a-MHC and h-MHC) antibody. No significant
alterations in protein contents for MHC, MLC and troponin
(TnI) were observed in rats with MI with or without any
drug treatments (Fig. 2). It should be noted that during
polyacrylamide gel electrophoresis, h-MHC exhibited a
higher electrophoretic mobility than a-MHC, which was
the dominant (>90%) isoform in sham group (Fig 3). In MI
group, protein content for a-MHC was reduced significantly
while that for h-MHC was increased markedly (Fig. 3); h-
MHC content was increased from 6.5% to 29% of total
MHC in the viable tissue of LV whereas a-MHC content
was decreased from 93.5% to 71.0% of total MHC. Block-
ade of RAS with ENP, or LOS, partially prevented the
increase in h-MHC as well as the decrease in a-MHC due to, and/or losartan treatment for 5 weeks starting at 3 weeks after coronary
ENP LOS COM
272F 19 258F 15 267F 15
115F 8.5 116F 9.5 114F 8.6
8.9F 1.2# 9.0F 0.7# 8.5F 0.6#
9521F 459# 9362F 562# 9533F 625#
10,057F 1012# 9895F 762# 9959F 721#
95F 7 101F 7 97F 5
ted treated with enalapril; LOS: myocardial infarcted treated with losartan;
ventricular end diastolic pressure; LVSP: left ventricular systolic pressure;
Fig. 2. Typical immunoblots and relative protein contents of myosin heavy chain (MHC) (A), myosin light chain (MLC) (B), and troponin I (TnI) (C) in the left
ventricles from Sham, infarcted (MI), enalapril-treated infarcted (ENP), losartan-treated infarcted (LOS), and combined enalapril and losartan-treated infarcted
(COM) rats. ENP and/or LOS were given orally for 5 weeks starting at 3 weeks after inducing MI. Values are meansF S.E. of seven animals for each group.
*P < 0.05 vs. Sham; #P < 0.05 vs. MI.
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additive effects (Fig 3).
3.4. Gene expression for a-MHC and b-MHC
The mRNA levels for a-MHC and b-MHC were deter-
mined by Northern blot analysis (Fig. 4). The a-MHC
mRNA level was decreased by 39% and that for b-MHC
mRNA was increased by 125% in LV from the infarctedFig. 3. Myosin heavy chain a- and h- isozymes (a-MHC and h-MHC) in
left ventricles from Sham, infarcted (MI), enalapril-treated infarcted (ENP),
losartan-treated infarcted (LOS), and combined enalapril and losartan-
treated infarcted (COM) rats. The figure shows typical immunoblots for
a-MHC and h-MHC-isozymes and results for laser densitometric analysis.
ENP and/or LOS were given orally for 5 weeks starting at 3 weeks after
inducing MI. Values are meansF S.E. of seven animals for each group.
*P < 0.05 vs. Sham; #P < 0.05 vs. MI.rats. These changes were partially reversed by treatment
with ENP, LOS and COM. The mRNA levels for MLC in
the sham group were not different from those in the
untreated and drug treated MI groups (Fig. 4).4. Discussion
In this study, heart failure due to MI was found to be
associated with depressed myofibrillar Ca2 +-stimulated
ATPase activity and a shift in MHC isozymes. Both + dP/
dt and  dP/dt were decreased whereas LVEDP was mark-
edly increased indicating cardiac dysfunction in the infarct-
ed animals. In addition, a decrease in myofibrillar ATPase
activity, an increase in b-MHC protein and gene expression,
as well as a decrease in a-MHC protein and gene expression
were also evident in hearts following MI. These hearts were
hypertrophied as the heart wt/body wt ratio was increased
and the animals showed signs of CHF as the lung wet wt/dry
wt ratio was also increased. These results, showing de-
pressed cardiac function and myofibrillar ATPase activity as
well as changes in MHC protein and gene expression, are in
agreement with our results reported previously in this
experimental model [9,25–27]. In view of the critical role
of a-MHC and b-MHC in determining the velocity of
cardiac contraction [1–4], it is likely that the depressed
myofibrillar Ca2 +-stimulated ATPase activity in the failing
heart may be due to the observed increase in b-MHC protein
content and a decrease in a-MHC protein content. Since the
protein content of total MHC was not altered, it appears that
there occurs a shift in MHC isozymes in the failing
myocardium. Such a change in the protein contents of
MHC isozymes seems specific because the protein content
  
 
 
 
 
 
Fig. 4. Typical Northern blots showing mRNA abundance for myosin heavy chain a-isozyme (A), myosin heavy chain h-isozyme (B), and myosin light chain
(C) in left ventricles from Sham, infarcted (MI), enalapril-treated infarcted (ENP), losartan-treated infarcted (LOS), and combined enalapril and losartan-treated
infarcted (COM) rats. a-MHC: mRNA blot for myosin heavy chain a-isozyme; h-MHC: mRNA blot for myosin heavy chain h-isozyme; MLC: mRNA blot for
myosin light chain; GAPDH: mRNA blot for glyceraldehyde-3-phosphate dehydrogenase; 28S/18S: the quality of mRNA preparation is evident from the
ethidium bromide staining of the 28S and 18S ribosomal RNA. Values are meansF S.E. of seven animals for each group. *P < 0.05 vs. Sham; #P < 0.05 vs. MI.
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Since we did not determine the absolute values for the MHC
isozymes in the failing heart by employing mass spectros-
copy [28], some caution should be exercised while inter-
preting the observed changes in a-MHC and b-MHC in
terms of quantitative alterations in myofibrillar protein
contents. Nonetheless, the observed alterations in the rela-
tive values for protein contents of MHC isozymes can be
seen to result in changes in the composition as well as
molecular structure of myofibrils and thereby represent the
process of myofibrillar remodeling during the development
of heart failure. This process of myofibrillar remodeling in
the failing heart may occur at the level of gene expression as
mRNA levels for a-MHC were decreased and those for b-
MHC were increased. Since such a remodeling has also
been shown to occur in the sarcoplasmic reticulum in CHF
due to MI [15], it is likely that remodeling of both
sarcoplasmic reticulum and myofibrils may be involved in
the development of cardiac dysfunction in the failing heart.
Treatment of infarcted animals with enalapril, an ACE
inhibitor, was observed to partially prevent alterations in
cardiac hypertrophy, lung congestion, heart function, myo-
fibrillar ATPase activity and a shift in MHC isozyme protein
and gene expression. Since neither enalapril nor losartan
affected the protein contents and mRNA levels for MLC, it
is evident that the observed effect of these drugs in MHC
protein and gene expression is specific in nature. These
results are consistent with the beneficial effects of imidapril,an ACE inhibitor, reported earlier in this experimental
model [9]. Since the effect of both enalapril and imidapril
were simulated by losartan, an AT1R antagonist, it appears
that the beneficial actions of both enalapril and imidapril on
heart function and cardiac as well as myofibrillar remodel-
ing are due to the blockade of RAS in animals with heart
failure. Both enalapril and losartan as well as other ACE
inhibitors such as captopril and trandolapril have also been
shown to partially prevent cardiac remodeling and changes
in sarcoplasmic reticular function, protein content and gene
expression in the failing hearts [13,15,29,30]. Furthermore,
treatment of infarcted animals with imidapril was found to
partially prevent changes in sarcolemmal phospholipase C
isozyme expression [31]. Thus, it is evident that the block-
ade of RAS may play a critical role in preventing cardiac
and subcellular remodeling. However, it is unlikely that the
beneficial effects of the RAS blockade on cardiac and
subcellular remodeling in infarcted animals are due to
reduction in the afterload because we did not observe any
change in the MAP upon treatments with ACE inhibitors or
losartan. Since ACE inhibitors are also known to prevent the
breakdown of bradykinin [32,33], it can be argued that the
beneficial effects of both enalapril and imidapril are medi-
ated through the actions of bradykinin. Although we have
not carried out any experiment to rule out this possibility,
this mechanism in the experimental model used may not be
of any major significance. This view is based on our
observation that the combination therapy with both enalapril
J. Wang et al. / Biochimica et Biophysica Acta 1690 (2004) 177–184 183and losartan did not produce an additive effect on heart
dysfunction or myofibrillar remodeling.5. Conclusions
The results presented here demonstrate that the depressed
myofibrillar ATPase activity and the shift in a-MHC and b-
MHC protein and gene expressions due to MI were partially
prevented by enalapril or losartan. These observations lend
further support to the concept regarding the occurrence of
subcellular remodeling in heart failure [34]. Since the
combined therapy with enalapril and losartan prevents
changes in heart function and myofibrillar remodeling
partially, it appears that other mechanisms such as the
activation of sympathetic nervous system [32,35,36], in
addition to the activation of RAS, may also be participating
in the genesis of cardiac dysfunction and myofibrillar
remodeling during the development of heart failure. Thus,
extensive work needs to be carried out to understand the
exact mechanisms for the development of cardiac dysfunc-
tion and subcellular remodeling in different experimental
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